1
|
Fortanier E, Berling E, Zanin A, Le Guillou A, Micaleff J, Nicolas G, Lozeron P, Attarian S. Reply to letter on What biological markers could be used for diagnosis and monitoring of nitrous oxide abuse. Eur J Neurol 2024; 31:e16187. [PMID: 38124455 DOI: 10.1111/ene.16187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 12/08/2023] [Indexed: 12/23/2023]
Affiliation(s)
- Etienne Fortanier
- Reference Center for Neuromuscular Diseases and amyotrophic lateral sclerosis, La Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Edouard Berling
- APHP, Service de Neurologie, Hôpital Raymond Poincaré, Centre de Référence Nord-Est-Ile-de-France, FHU PHENIX, Garches, France
- Université de Versailles Saint-Quentin-en-Yvelines, U1179 INSERM, Paris-Saclay, France
| | - Adrien Zanin
- Service de Physiologie Clinique-Explorations Fonctionnelles, DMU DREAM, APHP, Hôpital Lariboisière, Paris, France
- Laboratory for Vascular Translational Science, INSERM, U1148, Université de Paris, Paris, France
| | | | - Joelle Micaleff
- Marseille University Hospital, Clinical Pharmacology and Pharmacosurveillance, Regional Addictovigilance Center of Marseille, Marseille, France
- INSERM UMR1106, Aix-Marseille University, Marseille, France
| | - Guillaume Nicolas
- APHP, Service de Neurologie, Hôpital Raymond Poincaré, Centre de Référence Nord-Est-Ile-de-France, FHU PHENIX, Garches, France
- Université de Versailles Saint-Quentin-en-Yvelines, U1179 INSERM, Paris-Saclay, France
| | - Pierre Lozeron
- Service de Physiologie Clinique-Explorations Fonctionnelles, DMU DREAM, APHP, Hôpital Lariboisière, Paris, France
- Laboratory for Vascular Translational Science, INSERM, U1148, Université de Paris, Paris, France
| | - Shahram Attarian
- Reference Center for Neuromuscular Diseases and amyotrophic lateral sclerosis, La Timone University Hospital, Aix-Marseille University, Marseille, France
- INSERM, GMGF, Aix-Marseille University, Marseille, France
| |
Collapse
|
2
|
Fortanier E, Berling E, Zanin A, Guillou AL, Micaleff J, Nicolas G, Lozeron P, Attarian S. How to distinguish Guillain-Barré syndrome from nitrous oxide-induced neuropathy: A 2-year, multicentric, retrospective study. Eur J Neurol 2023; 30:3296-3306. [PMID: 37494104 DOI: 10.1111/ene.15998] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 07/10/2023] [Accepted: 07/20/2023] [Indexed: 07/27/2023]
Abstract
BACKGROUND Recreational use of nitrous oxide (N2 O) has dramatically increased in recent years, resulting in numerous cases of acute sensorimotor tetraparesis secondary to nitrous oxide-induced neuropathy (N2 On). Challenging clinical features can mimic Guillain-Barré syndrome (GBS), the main differential diagnosis upon admission. The most sensitive biomarkers for distinguishing between these two conditions remain to be determined. METHODS Fifty-eight N2 On patients from three referral centers were retrospectively included over a 2-year period and compared to GBS patients hospitalized during the same timeframe (47 patients). Collected demographic, clinical, biological, and electrophysiological data were compared between the two groups. RESULTS The typical N2 On clinical pattern included distal sensorimotor deficit in lower limbs with absent reflexes, proprioceptive ataxia, and no cranial involvement (56.7% of our cohort). Misleading GBS-like presentations were found in 14 N2 On patients (24.1%), and 13 patients (22.4%) did not report N2 O use during initial interview. Only half the N2 On patients presented with reduced vitamin B12 serum levels upon admission. A slightly increased cut-off (<200 pmol/L) demonstrated 85.1% sensitivity and 84.5% specificity in distinguishing N2 On from GBS. Only 6.9% of N2 On patients met the criteria for primary demyelination (p < 0.01), with only one presenting conduction blocks. A diagnostic algorithm combining these two biomarkers successfully classified all GBS-like N2 On patients. CONCLUSIONS Vitamin B12 serum level < 200 pmol/L cut-off and conduction blocks in initial electrophysiological study are the two most sensitive biomarkers for rapidly distinguishing N2 On from GBS patients. These two parameters are particularly useful in clinically atypical N2 On with GBS-like presentation.
Collapse
Affiliation(s)
- Etienne Fortanier
- Reference Center for Neuromuscular Diseases and ALS, La Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Edouard Berling
- APHP, Service de Neurologie, Hôpital Raymond Poincaré, Centre de référence Nord-Est-Ile-de-France, FHU PHENIX, Garches, France
- Université de Versailles Saint-Quentin-en-Yvelines, U 1179 INSERM, Paris-Saclay, France
| | - Adrien Zanin
- Service de Physiologie Clinique-Explorations Fonctionnelles, DMU DREAM, APHP, Hôpital Lariboisière, Paris, France
- Laboratory for Vascular Translational Science, U1148, Université de Paris, INSERM, Paris, France
| | | | - Joelle Micaleff
- Marseille University Hospital, Clinical Pharmacology and Pharmacosurveillance, Regional Addictovigilance Center of Marseille, Marseille, France
- Aix-Marseille University, INSERM UMR 1106, Marseille, France
| | - Guillaume Nicolas
- APHP, Service de Neurologie, Hôpital Raymond Poincaré, Centre de référence Nord-Est-Ile-de-France, FHU PHENIX, Garches, France
- Université de Versailles Saint-Quentin-en-Yvelines, U 1179 INSERM, Paris-Saclay, France
| | - Pierre Lozeron
- Service de Physiologie Clinique-Explorations Fonctionnelles, DMU DREAM, APHP, Hôpital Lariboisière, Paris, France
- Laboratory for Vascular Translational Science, U1148, Université de Paris, INSERM, Paris, France
| | - Shahram Attarian
- Reference Center for Neuromuscular Diseases and ALS, La Timone University Hospital, Aix-Marseille University, Marseille, France
- Aix-Marseille University, INSERM, GMGF, Marseille, France
| |
Collapse
|
3
|
Compagnone NA, Blanc B, Picamal P, Galluzzi S, Marizzoni M, Jovicich J, Frisoni GB, Forloni G, Albani D, Richardson J, Parnetti L, Tsolaki M, Nobili F, Bartes-Faz D, Didic M, Schonknecht P, Payoux P, Soricelli A, Rossini P, Visser PJ, Bordet R, Fiedler U, Blin O, Micaleff J, Lanteaume L. P4‐077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG
®
TEST ENABLE STRATIFICATION OF PRE‐DEMENTIA ALZHEIMER'S DISEASE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
| | | | | | - Samantha Galluzzi
- Lab Alzheimer's Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico, FatebenefratelliBresciaItaly
| | - Moira Marizzoni
- Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Giovanni B. Frisoni
- Lab Alzheimer's Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico, FatebenefratelliBresciaItaly
| | - Gianluigi Forloni
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | - Diego Albani
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | - Jill Richardson
- GSK Research and Development, China‐UKHertfordshireUnited Kingdom
| | | | - Magda Tsolaki
- First Department of NeurologyAHEPA University Hospital, MakedoniaThessalonikiGreece
| | | | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
| | | | - Pierre Payoux
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | - Andrea Soricelli
- SDN Istituto di Ricerca Diagnostica e Nucleare SpA per la Ricerca e l'Alta Formazione in Diagnostica NucleareNaplesItaly
| | - Paolo Rossini
- Department of Gerontology, Neurosciences and OrthopedicsCatholic UniversityRomeItaly
| | - Pieter Jelle Visser
- Alzheimer Center and Department of Neurology, Amsterdam NeuroscienceVU University Medical CenterAmsterdamNetherlands
| | - Régis Bordet
- Service de Pharmacologie-Hôpital Huriez-Centre Hospitalier Régional UniversitaireLilleFrance
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Olivier Blin
- Aix-Marseille UniversityCentre National de la Recherche ScientifiqueMarseilleFrance
| | - Joelle Micaleff
- Service de Neurologie et NeuropsychiatryCentre Hospitalier Universitaire la TimoneMarseilleFrance
| | | |
Collapse
|
4
|
Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontés M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 2007; 17:248-53. [PMID: 17303424 DOI: 10.1016/j.nmd.2006.12.008] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2006] [Revised: 11/27/2006] [Accepted: 12/16/2006] [Indexed: 10/23/2022]
Abstract
Charcot-Marie-Tooth [CMT] syndrome is the most common hereditary peripheral neuropathy. CMT1A, which accounts for 50% of all CMT cases, usually results from triploidy of the PMP22 gene. Preclinical trials using an animal model show that disabled mice force-fed with high doses of ascorbic acid partially recover muscular strength after a few months of treatment, and suggest that high doses of ascorbic acid repress PMP22 expression. In this study, we demonstrated that ascorbic acid represses PMP22 gene expression by acting on intracellular cAMP levels and adenylate cyclase activity. This action is dose dependent and specific to ascorbic acid, since repression is not observed after treatment with other antioxidants. The new properties of ascorbic acid are discussed, along with the implications of these findings for CMT disease treatment.
Collapse
Affiliation(s)
- Ferdinand Kaya
- INSERM UMR491, Centre de Thérapie Génique, Génomique et de Biothérapies (CTGGB), IPHM-IFR125, Faculté de Médecine de la Timone, 27 bd Jean Moulin, 13385 Marseille cedex 5, France
| | | | | | | | | | | |
Collapse
|